Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Tanaka K, Toyota S, Akiyama M, Wakimoto N, Nakamura Y, Najima Y, Doki N, Kakihana K, Igarashi A, Kobayashi T, Ohashi K, Kudo D, Shinagawa A, Takano H, Fujio T, Okoshi Y, Hori M, Kumagai T, Saito T, Mukae J, Yamamoto K, Tsutsumi I, Komeno T, Yoshida C, Yamamoto M, Kojima H; on behalf of the Ochanomizu Hematology Study Group. Tanaka K, et al. Among authors: hori m. Acta Haematol. 2019;141(2):111-118. doi: 10.1159/000495338. Epub 2019 Feb 6. Acta Haematol. 2019. PMID: 30726834 Clinical Trial.
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma.
Cho Y, Hori M, Okoshi Y, Fujisawa F, Shinagawa A, Kudo D, Komeno T, Yoshida C, Katsura Y, Ota I, Shimizu S, Kamoshita M, Sasaki K, Tanaka K, Mukai HY, Kojima H. Cho Y, et al. Among authors: hori m. Acta Haematol. 2015;134(1):25-31. doi: 10.1159/000369445. Epub 2015 Apr 3. Acta Haematol. 2015. PMID: 25871926 Clinical Trial.
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia.
Yoshida C, Komeno T, Hori M, Kimura T, Fujii M, Okoshi Y, Suzukawa K, Chiba S, Hasegawa Y, Mukai HY, Ito T, Shimizu S, Kamoshita M, Kudo D, Shinagawa A, Chikatsu N, Monma Y, Watanabe N, Kojima H. Yoshida C, et al. Among authors: hori m. Int J Hematol. 2011 May;93(5):618-623. doi: 10.1007/s12185-011-0838-3. Epub 2011 Apr 22. Int J Hematol. 2011. PMID: 21523339
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
Kubo K, Hori M, Ohta K, Handa H, Hatake K, Matsumoto M, Hagiwara S, Ohashi K, Nakaseko C, Suzuki K, Ito S, Kinoshita G, Shelat SG, Miyoshi M, Takezako N. Kubo K, et al. Among authors: hori m. Int J Hematol. 2020 Jan;111(1):65-74. doi: 10.1007/s12185-019-02757-0. Epub 2019 Nov 7. Int J Hematol. 2020. PMID: 31701481 Clinical Trial.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. Among authors: hori m. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy.
Suzuki A, Kakugawa S, Miyoshi M, Hori M, Suzuki K, Furukawa Y, Ohta K. Suzuki A, et al. Among authors: hori m. Leukemia. 2020 Nov;34(11):3088-3090. doi: 10.1038/s41375-020-0860-7. Epub 2020 May 12. Leukemia. 2020. PMID: 32398792 No abstract available.
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Yao D, Das P, San-Miguel J. Dimopoulos MA, et al. Among authors: hori m. J Clin Oncol. 2023 Jan 20;41(3):568-578. doi: 10.1200/JCO.21.02815. Epub 2022 Aug 12. J Clin Oncol. 2023. PMID: 35960908 Free PMC article. Clinical Trial.
3,196 results